Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.

Ehlers L, Andersen G, Clausen LB, Bech M, Kjølby M.

Stroke. 2007 Jan;38(1):85-9. Epub 2006 Nov 22.

2.
3.

Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.

Tung CE, Win SS, Lansberg MG.

Stroke. 2011 Aug;42(8):2257-62. doi: 10.1161/STROKEAHA.111.615682. Epub 2011 Jun 30.

4.

Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.

Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B.

Stroke. 2013 Aug;44(8):2269-74. doi: 10.1161/STROKEAHA.113.001295. Epub 2013 Jun 18.

5.

A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.

Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL.

Ann Emerg Med. 2013 Jan;61(1):46-55. doi: 10.1016/j.annemergmed.2012.04.020. Epub 2012 May 24.

6.

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.

Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J.

Stroke. 2004 Jun;35(6):1490-7. Epub 2004 Apr 22.

7.

A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.

Yan X, Hu HT, Liu S, Sun YH, Gao X.

Neurol Res. 2015 Apr;37(4):352-8. doi: 10.1179/1743132814Y.0000000447. Epub 2014 Oct 8.

PMID:
25297471
8.

Cost-effectiveness analysis of thrombolytic treatment for stroke.

Mar J, Begiristain JM, Arrazola A.

Cerebrovasc Dis. 2005;20(3):193-200. Epub 2005 Jul 27.

PMID:
16088115
9.

Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.

Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, Liu G, Liu L, Wang C, Wang Y, Wang Y; TIMS-CHINA Investigators.

PLoS One. 2014 Oct 20;9(10):e110525. doi: 10.1371/journal.pone.0110525. eCollection 2014.

10.

Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.

Jones ML, Holmes M.

Health Technol Assess. 2009 Sep;13 Suppl 2:15-21. doi: 10.3310/hta13suppl2/03. Review.

11.

Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.

Earnshaw SR, Jackson D, Farkouh R, Schwamm L.

Stroke. 2009 May;40(5):1710-20. doi: 10.1161/STROKEAHA.108.540138. Epub 2009 Mar 12.

12.

Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke.

Araújo DV, Teich V, Passos RB, Martins SC.

Arq Bras Cardiol. 2010 Jul;95(1):12-20. Epub 2010 Jun 11. English, Portuguese.

13.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

14.

Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.

Quinn TJ, Dawson J.

Expert Rev Pharmacoecon Outcomes Res. 2009 Dec;9(6):513-22. doi: 10.1586/erp.09.63. Review.

PMID:
19941428
15.

Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom.

Earnshaw SR, McDade C, Chapman AM, Jackson D, Schwamm L.

Clin Ther. 2012 Jul;34(7):1544-58. doi: 10.1016/j.clinthera.2012.05.004. Epub 2012 Jun 12.

PMID:
22695225
16.

Bayesian cost-effectiveness analysis. An example using the GUSTO trial.

Fryback DG, Chinnis JO Jr, Ulvila JW.

Int J Technol Assess Health Care. 2001 Winter;17(1):83-97.

PMID:
11329847
17.

Is hospitalization after TIA cost-effective on the basis of treatment with tPA?

Nguyen-Huynh MN, Johnston SC.

Neurology. 2005 Dec 13;65(11):1799-801.

PMID:
16344525
18.

Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.

Hougaard KD, Hjort N, Zeidler D, Sørensen L, Nørgaard A, Thomsen RB, Jonsdottir K, Mouridsen K, Hansen TM, Cho TH, Nielsen TT, Bøtker HE, Østergaard L, Andersen G.

Int J Stroke. 2013 Feb;8(2):141-6. doi: 10.1111/j.1747-4949.2012.00786.x. Epub 2012 Mar 30.

PMID:
22463392
19.

Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.

Perlroth DJ, Sanders GD, Gould MK.

Arch Intern Med. 2007 Jan 8;167(1):74-80.

PMID:
17210881
20.

Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL.

Stroke. 2014 Oct;45(10):3032-9. doi: 10.1161/STROKEAHA.114.005852. Epub 2014 Sep 4.

Supplemental Content

Support Center